Revium Rx. (RVRC): Net Income

Annual figures by period end, from SEC filings.

-$13.45M

Year ended 2025-12-31

-$13.25M

Trailing 12 months to 2026-06-30

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$13.45M	n/a	2026-03-31, From 2025-01-01

Net Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Revium Rx. (RVRC)	2025-12-31	-$13.45M	n/a
Lunai Bioworks Inc. (LNAI)	2025-06-30	-$178.01M	n/m
Xenetic Biosciences, Inc. (XBIO)	2025-12-31	-$2.68M	n/m
GT Biopharma, Inc. (GTBP)	2025-12-31	-$28.35M	n/m
CNS Pharmaceuticals, Inc. (CNSP)	2025-12-31	-$15.85M	n/m
GRI Bio, Inc. (GRI)	2025-12-31	-$11.96M	n/m
IGC Pharma, Inc. (IGC)	2025-03-31	-$7.12M	n/m
Dermata Therapeutics, Inc. (DRMA)	2025-12-31	-$7.56M	n/m
Processa Pharmaceuticals, Inc. (PCSA)	2025-12-31	-$13.56M	n/m

Compare RVRC, LNAI, XBIO, GTBP side by side · Screen every company in Pharmaceutical Preparations ↗